Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MPI 5003

Drug Profile

MPI 5003

Alternative Names: AccuSite; Fluorouracil/epinephrine injectable gel

Latest Information Update: 24 Jun 1999

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Chiron Corporation
  • Developer ALTANA Group; Chiron Corporation; Dompe; Savage Laboratories
  • Class
  • Mechanism of Action Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Market Withdrawal Human papillomavirus infections
  • Discontinued Basal cell cancer; Kaposi's sarcoma; Psoriasis; Squamous cell cancer

Most Recent Events

  • 24 Jun 1999 Discontinued-II for Kaposi's sarcoma in United Kingdom (Intralesional)
  • 24 Jun 1999 Discontinued-II for Squamous cell cancer in Australia (Intralesional)
  • 24 Jun 1999 Discontinued-II for Squamous cell cancer in USA (Intralesional)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top